Access cutting-edge systemic sclerosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access systemic sclerosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic sclerosis treatment provided free
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1
Sponsor: aTyr Pharma, Inc.
Check if you qualify for this systemic sclerosis clinical trial in New York, NY
If you're searching for systemic sclerosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.